ME
Therapeutic Areas
MAX BioPharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Oxy210 | Metabolic dysfunction-associated steatohepatitis (MASH) | Preclinical |
| Oxysterol Platform (Fibrosis) | Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases | Preclinical |
| Oxysterol Platform (Inflammation) | Atherosclerosis, obesity, inflammaging, cystic fibrosis, dermatological conditions | Preclinical |
| Oxysterol Platform (Antiviral) | Hepatitis B, Hepatitis C, SARS-CoV-2, HIV | Preclinical |
| Oxysterol Platform (Orthopedics) | Spinal fusion, fracture healing | Preclinical |
Leadership Team at MAX BioPharma
FP
Farhad Parhami, Ph.D., M.B.A.
Founder, President & CEO
FS
Frank Stappenbeck, Ph.D.
Director of Chemistry
GP
Gonzalo Payan
Director of Finance & Operations
FW
Feng Wang, Ph.D.
Director of Molecular and Cellular Biology
WM
William Matsui, M.D.
Scientific Co-Founder